Posted on

ESG reporting: Hang Seng companies have transparency shortcomings

HONG KONG, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Companies in the Hang Seng Index rank in the midrange internationally in terms of the quality of their ESG reporting. This is the finding of the Global ESG Monitor 2022 (GEM), Regional Report Hong Kong/China (https://globalesgmonitor.com/download-report/), published today. The GEM is considered an international leader in analysing the non-financial reporting of leading companies in Europe, North America, Asia and Australia. According to the latest GEM study, the companies listed in the Hang Seng Index score an average of 57 points out of a maximum possible 100 points for the transparency of their non-financial reports. This result places the Hang Seng Index at the lower end of the midrange among the total of ten international indices from North America, Europe, Asia and Australia that were examined as part of the GEM, and ranks just above the level of S&P Asia (56 points) and Australia's ASX50 (53 points).At the top of the index league are three companies - sports equipment supplier Anta Sports Products (02020.HK), financial services provider Hang Seng Bank (00011.HK) and Internet services provider and software developer Tencent Holdings (00700.HK) - on a score of 77. Sands China (01928.HK) and HSBC Holdings (00005.HK) rank the 4th and 5th among the blue chips with 75 and 74 points respectively. Other companies among the top ten include Lenovo Group (00992.HK), Power Assets (00006.HK), Henderson Land Development (00012.HK), China Mobile (Hong Kong) (00941.HK) and Hang Lung Properties (00101.HK). With a rate of 97 percent, a generally high level of willingness exists among Hang Seng Index companies to base their non-financial reporting on a standard international framework. In a global comparison, however, they tend to be more focused with an average of 6.7 referenced frameworks and standards. This is also reflected, among other things, in the length of the reports, which rank among the most concise of the ten indices examined. "As you go through the Hang Seng data, you then notice that this focus is not always an advantage," comments Ariane Hofstetter, co-founder and Head of Research and Data Science at GEM. "In many cases, there's a lack of important details that would lead to better comprehensibility, reliability and comparability of the data."Contextual information such as company size, number of employees and product and service portfolio is comparatively well established in non-financial reporting. Four out of five companies surveyed (81 percent) also describe the environmental parameters in which they operate. However, Hang Seng companies are less likely to address socioeconomic or political conditions (75 percent and 54 percent respectively). And only one-third (32 percent) from this group report on their value chains. "Greater sustainability nevertheless also requires close collaboration along the entire supply chain. How well Hang Seng companies achieve this undertaking remains in part an open question. Because here, too, there's a lack of information that enables the information to be classified," notes Michael Diegelmann, co-founder of GEM. "Although 83 percent of the reports contain descriptions of supply chains, once again there's a lack of detail to help rank the risks associated with the supply chain." For example, slightly less than a third of the companies provide information on the type of suppliers they do business with, and just under half state the estimated number of suppliers along the supply chain.The relevant topics of Environment, Social and Governance are covered by a majority of Hang Seng companies in their non-financial reports. Around a third, for example, say they are already climate-neutral. A further 44 percent aim to achieve this objective in the future. In contrast to this statement, however, only three-quarters of companies identify their main sources of emissions in their reports and outline the biggest challenges they face in terms of climate-related emissions.In the area of social issues, the topic of employee and human rights is not one of the most present in Hang Seng reporting. For example, 82 percent fail to state the extent to which specific incidents of discrimination and harassment have occurred. In contrast, the reports reflect more transparency on the subject of health and safety, where 89 percent of companies state their position - even though only seven out of ten companies report more specifically on "the number and rate of fatalities due to work-related injuries" and only a quarter provide information on "the number and rate of work-related injuries with serious consequences".When it comes to governance, reporting by Hang Seng companies tends to focus more on structures and less on the functioning of the supervisory board. Around seven out of ten companies report how they ensure or promote their supervisory boards' collective knowledge about financial and non-financial issues and decisions. Only just under two-thirds of the companies (64 percent) report on the supervisory board's role when it comes to assessing environmental and social risk management. The scores are particularly low in connection with critical concerns and issues reported to the supervisory board. Here, only a quarter of the companies provide information, with only four percent then being specific and outlining the total number of critical concerns that were communicated to the supervisory board. "One reason many reports lack detail and transparency is that they are prepared according to the HKEX ESG reporting guidelines," is Diegelmann's assessment. "This is where it then becomes noticeable that these guidelines have lower minimum requirements and don't go into much depth, especially compared to the Global Reporting Initiative requirements."Among Hang Seng Index companies, it is also striking that there is little willingness to submit the non-financial report to an auditor. Only just under one-third of issuers (32 percent) issue a corresponding audit engagement. It is striking that in 70 percent of the cases no information was provided on the depth of the audit and only 16 percent of the reports were audited with "reasonable assurance"."Hang Seng companies are generally convinced that their development towards greater sustainability must be accompanied by appropriate reporting," is the conclusion of Joanne Chan, Regional Partner Hong Kong and Managing Director at LBS Communications Consulting Limited. "However, an enormous amount of work will be required for Hang Seng companies to ensure that their reports can contribute to sustainable change through transparency."Full report : https://globalesgmonitor.com/download-report-form/For more information on the rating criteria and details of the report, please visit https://lbs-comm.com/global-esg-monitor-2022-report-scorings-is-out-now-two-hong-kong-companies-were-ranked-top-ten/About the Global ESG Monitor (GEM)The Global ESG Monitor (GEM) is a unique research initiative to examine transparency in non-financial reporting of the largest companies in the world. The GEM monitors, analyzes and reports on the transparency of non-financial ESG reporting using the GEM ASSAYTM, a proprietary research tool adapted annually in response to evolving conditions and developments. The operationalization of transparency underlying the GEM ASSAYTM is based on the relevant guidelines of Global Reporting Initiative (GRI), ISO Standard 26000, World Economic Forum (WEF) and Accountability. If you have any media enquiries, please contact LBS Communications Consultants Limited.www.lbs-forum.comJoanne Chan Tel : (852)3679 3671 Email : jchan@lbs-comm.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Announces 2022 Q3 Results

HONG KONG, Nov 10, 2022 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods" or the "Company", and together with its subsidiaries, the "Group"; Stock code: 1475) today announced its financial results for the nine months ended 30 September 2022 ("the Reporting Period"). Revenue of the Group increased solidly by 7.8% year-on-year ("YoY") from HK$2,858.6 million to HK$3,081.9 million. Revenue from Hong Kong and China operations respectively grew 11.6% to HK$1,156.6 million and 5.7% to HK$1,925.2 million YoY. Gross profit grew 8.2% YoY to HK$973.5 million (2021: HK$899.4 million) with gross profit margin increased by 0.1 percentage point to 31.6% (2021: 31.5%). Profit attributable to owners of the Company was HK$237.3 million.The growth in overall gross profit margin and revenue of Hong Kong and Mainland China operations is mainly due to the price adjustments implemented during the Reporting Period. Moreover, for Hong Kong operations, good demand for instant noodles and frozen foods contributed to the revenue growth. For Mainland China operations, growth in sales volume for the cup-type instant noodles also benefits its revenue increase during the Reporting Period.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "The Group achieved resilient business performance in Hong Kong and Mainland China in spite of global and regional uncertainties during the Reporting Period, thanks to the prudent strategies such as cost-saving measures and price adjustment we implemented. Looking forward, we will remain conscious of the business environment and take necessary measures to improve our production efficiency and flexibility, as well as to enhance our product portfolio in order to delight our consumers and create long-term value for all stakeholders."About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the "ECO Cup" concept and primarily focuses its sales efforts in first-and second-tier cities. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Wins Bid for Acquiring Equity Interest in Zhuhai Winner at RMB352.44 Million

HONG KONG, Nov 7, 2022 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods", and together with its subsidiaries, the "Group"; Stock code: 1475) announced that its wholly-owned subsidiary Nissin Foods (China) Holding Co., Ltd. ("Nissin Foods China") has won a bid for 29.55% equity interest in Zhuhai Golden Coast Winner Food Products Limited ("Zhuhai Winner") (the "Proposed Acquisition") at RMB352.44 million.An indirect subsidiary of Nissin Foods, Zhuhai Winner is 70.45% owned by Winner Food Products Limited, a wholly-owned subsidiary of the Company, and 29.55% owned by Zhuhai Western Development Co. Upon completion of the Proposed Acquisition, Zhuhai Winner will become an indirect wholly-owned subsidiary of Nissin Foods.Zhuhai Winner is a manufacturer and distributor of instant noodles for Nissin Foods. Its principal activities include production and sale of instant noodles, seasonings, paper food containers and plastic packaging containers. Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "We believe the Proposed Acquisition, if materialised, will give us greater flexibility to deploy production capabilities in Hong Kong and Mainland China to respond to market demand and the changing business environment. It will also present a good opportunity to the Group to advance our instant noodles production and distribution, as well as seize the long-term growth trends in the Mainland China, which will in turn bolster the Group's overall income and profitability. The move is also proof of our long-term commitment to the instant noodles business in Hong Kong and Mainland China which is in line with our strategic direction." About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the "ECO Cup" concept and primarily focuses its sales efforts in first-and second-tier cities. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk.For media enquiries:Nissin Foods Company LimitedPublic Relations DepartmentBlanche Wong / Mabel TanEmail: pr@nissinfoods.com.hkFor investor enquiries:Nissin Foods Company LimitedInvestor Relations DepartmentShingo Yamazaki / Fanny Yan Email: ir@nissinfoods.com.hkStrategic Financial Relations LimitedVicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hkAggie Fang Tel: (852) 2114 4987 Email: aggie.fang@sprg.com.hkMaggie Ko Tel: (852) 2864 4890 Email: maggie.ko@sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

China Risun’s 2022 Interim Revenue Ups 21.1% to RMB22.53 Billion, Profit Attributable to Owners was RMB1.74 Billion

HONG KONG, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - China Risun Group Limited ("China Risun", or the "Group", stock code: 1907), a leading global integrated coke, coking chemicals and refined chemicals producer and supplier and relevant operation management services provider in China, has announced its interim results for the six months ended 30 June 2022 ("the reporting period"). During the reporting period, the Group grew and expanded by way of provision of operation management services together with the formation and acquisition of entities by focusing on opportunities in both China and overseas. Revenue for the six months ended June 30, 2022 was approximately RMB22.53 billion, representing an increase of approximately 21.1%. Profit attributable to owners of the Company was approximately RMB1.74 billion, up approximately 0.8%. Basic earnings per share of the Company was RMB39.14 cents. To share the fruit of its outstanding results performance, the Board determined to declare an interim dividend of RMB12.30 cents per share (for the six months ended June 30, 2021: RMB12.30 cents).Steady expansion of coke businessSelf-built production progressing wellDuring the reporting period, revenue derived from the coke and coking chemicals manufacturing business continued to increase, up 20.2% to RMB9,262.7 million. As at January 1, 2022, the Group had the annual production capacity of coke amounting to approximately 11.05 million tons and there were two expansions of the production capacity of coke in Huhhot and Sulawesi Production Bases under construction. Trial run of the first phase of coke production facility with an annual capacity of 1,500,000 tons in Huhhot Production Base was completed and construction of the coke production facility with the remaining 1,500,000 tons per annum will be completed by the end of the first quarter of 2023. The expansion in Sulawesi Production Base will be completed in different phases in mid of 2023 and early 2024.For the operation management service section, the Group expanded the coke operation management services into Henan Province, the PRC in June 2022, where the Group is responsible for the provision of integrated sales and marketing services to a coke enterprise with an annual coke production volume of 1,000,000 tons. At the end of the reporting period, there are a number of operation management services carried out by the Group.Continue to enhance the production capacity of refined chemicals facilities Becoming one of the leading producers in the worldThe group's refined chemical manufacturing business continued to grow with revenue from this sector increased by 18.7% to RMB7,245.9 million. During the reporting period, the Group invested and enhanced the capacity of caprolactam (CPL) in the production line of aromatic chemicals in Cangzhou and Dongming Production Base, which can be used for manufacturing nylon, fibers and plastics. The Group estimated that the annual production capacity of CPL will be 750,000 tons by the end of 2022, ranking as one of the leading producers in the world.Accelerate the development of hydrogen energy business and achieve phased results The Group had hydrogen production, storage, transportation, hydrogenation to usage together with radiation of intelligent supply of hydrogen in three different production bases, which were Dingzhou, Xingtai and Huhhot. Among these three production bases, the hydrogen production facilities in Dingzhou with a daily production capacity of 13,000 kg and Dingzhou hydrogen refueling station commenced operation during the Reporting Period. China Risun is going to participate actively into the hydrogen industrialization plan in different cities in the PRC. In March 2022, the Group set up a new subsidiary in Baoding in Hebei Province, which will be engaged in the following businesses, (i) development of application of hydrogen energy heavy truck and hydrogen bus together with hydrogen-electric oil and gas energy stations; (ii) development of the transportation line for agricultural products from Baoding to Beijing and areas adjacent to Beijing; (iii) development of hydrogen bus application in Baoding; and (iv) long-distance hydrogen pipeline feasibility study and exploration on cost reduction of transportation of hydrogen. Moving forward, focusing on the rapid development of hydrogen energy industry in Beijing-Tianjin-Hebei area, the Group is committed to expanding its intelligent supply of hydrogen to the whole country with advanced technology and more customer-oriented services.Expand geographical layout to IndonesiaOpen up global marketThe Group expanded its geographical layout from the PRC to Indonesia in the second half of 2021 by establishing business partnerships by way of the formation of three joint ventures. Three joint ventures located in IMIP are under development as planned, with Risun Wei Shan New Energy (Indonesia) Company Limited expected to commence production gradually from the mid of 2023.Looking forward to the second half of 2022, the Group will continue to increase the market share in the independent coke market and certain refined chemicals market by expanding the annual coke production capacity, entering into different operation management services together with mergers and acquisitions (including forming joint ventures). The Group will also keep engaging in green and low-carbon practices, driving the industrial chain in the reduction of carbon emissions and striving to be one of the leaders in carbon peak and neutrality in the coke and chemical industry in the PRC.About China Risun Group LimitedChina Risun Group Limited is the world's largest independent producer and supplier of coke by volume in 2021, according to Frost & Sullivan. China Risun is an integrated coke, coking chemicals, refined chemicals and hydrogen energy products producer and supplier and relevant operation management services provider in China and occupies leading positions in a number of refined chemicals sectors both in China and globally. The vertically-integrated business model together with more than 27 years of experience in the coal chemicals industry production chain has enabled China Risun to further tap the downstream refined chemicals markets and hence diversify its income sources and create greater value. China Risun has been listed on the main board of the Hong Kong Stock Exchange since March 2019 and is now included in various index series, including the Hang Seng Composite Index, Hang Seng Composite Industry Index - Materials, Hang Seng Composite MidCap Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, Hang Seng Stock Connect Hong Kong Composite Index, Hang Seng Large-Mid Cap (Investable) Index, Hang Seng Large-Mid Cap Low Volatility Comprehensive Index, Hang Seng Large-Mid Cap Quality Comprehensive Index, Hang Seng Large-Mid Cap Low Size Comprehensive Index, Hang Seng Large-Mid Cap Dividend Yield Comprehensive Index, Hang Seng Large-Mid Cap Momentum Comprehensive Index, Hang Seng Large-Mid Cap Value Comprehensive Index, Hang Seng Large-Mid Cap Equal Weighted Factor Mix (QVLM) Index and Hang Seng Large-Mid Cap Risk Parity Factor Mix (QVLM) Index. China Risun is also included in FTSE GEIS: FTSE Global Small Cap Index, FTSE Global All-Cap Index (LMS) and FTSE Global Total-Cap Index (LMSu).For more details, please visit http://www.risun.com/En/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion

HONG KONG, Aug 23, 2022 - (ACN Newswire via SEAPRWire.com) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited Interim results for the six months ended 30 June 2022 (the "Period").Development Highlights-- The Group achieved considerable sales growth from a number of new products and oncology products, with sales of new products launched within five years accounted for approximately 43.5% of the Group's total revenue in the first half of 2022, up from approximately 36.9% for the same period last year.-- As of 30 June 2022, the Group had a total of 40 innovative drug candidates in the oncology field, 8 innovative drug candidates in the field of liver disease, 9 innovative drug candidates in the respiratory system field in development process for clinical application, and 1 innovative drug candidate in the field of surgery/analgesia in phase III clinical trial. Furthermore, the Group had a total of 23 biosimilar or generic drug candidates in the oncology field, 9 other biosimilar or generic drug candidates in the surgical/analgesic field, 5 biosimilar or generic drug candidates in the field of liver disease and 20 biosimilar or generic drug candidates in the respiratory system field in development process for clinical application.-- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022. To date, Anlotinib has been approved for five indications: third-line non-small cell lung cancer, third-line small cell lung cancer, soft tissue sarcoma, medullary thyroid cancer and differentiated thyroid cancer.-- TDI01 is a highly selective inhibitor of ROCK2 and is currently in development process of phase I clinical trial for the target indications of pneumoconiosis, pulmonary fibrosis and graft versus host disease. There is no approved drug for pneumoconiosis worldwide, TDI01 is expected to fill this gap and be a boon to pneumoconiosis patients. -- SFT-1001 and SFT-1003 are two soft mist inhalation products that are currently in late clinical stage. As of 2021, there are only five soft mist inhalation products available worldwide, with a global market size of over US$3 billion and a compound growth rate of over 35% in the past five years, and the global soft mist market is expected to each US$7 billion by 2030.During the Period, the Group recorded revenue of approximately RMB15.19 billion, an increase of approximately 5.9% against last year. Profit attributable to the owners of the parent company was approximately RMB1.92 billion. Earnings per share attributable to the owners of the parent company were approximately RMB10.30 cents. Excluding the share of profits and losses of associates and a joint venture (net of related tax and non-controlling interests), certain non-cash items and one-off adjustments, adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB1.66 billion, an increase of approximately 4.5% over that in the same period last year. Sales of new products accounted for approximately 43.5% of the Group's total revenue for the period, while it was approximately 36.9% for the same period last year. The Group's liquidity remains strong, with cash and bank balances classified under current assets of approximately RMB7.77 billion, bank deposits classified under non-current assets of approximately RMB6.84 billion, and wealth management products of approximately RMB7.64 billion in aggregate, the Group's total fund reserve was approximately RMB22.25 billion at the period end.The Board of Directors has declared the payment of an interim dividend of HK6 cents per share. (2021: HK4 cents).Sales: Harvested years of R&D results, sales of new products as a percentage to revenue climbedThe Group has obtained significant benefits from years of high research and development, and continues to focus on development of related products in the areas of specialist therapeutic. During the period, the sales revenue of new products launched within five years was approximately RMB6.61 billion, accounting for approximately 43.5% of the total revenue of the Group from approximately 36.9% last year.During the Period, the Group's oncology, liver disease and cardio-cerebral vascular medicines continued to lead in sales contribution. Sales of oncology medicines increased by 16.7% year-on-year to approximately 4.96 billion, accounting for approximately 32.6% of the Group's revenue. Sales of liver disease (hepatitis) medicines and cardio-cerebral vascular medicines increased by approximately 11.1% and 13.8% year-on-year to approximately 2.01 billion and 1.55 billion, respectively, accounting for approximately 13.2% and 10.2% of the Group's revenue. In addition, the sales contributions of products in various areas such as surgery/analgesia, respiratory system and others went up hand-in-hand. Sales of surgery/analgesia and respiratory system medicines accounted for approximately 16.6% and 10.0% of the Group's revenue, respectively.In the area of oncology, since its launch in 2018, the revenue from sales of Anrotinib has continued to grow rapidly and is expected to grow at a compound rate of 46% in the period between 2018 and 2022. During the Period, sales of Annike (Penpulimab monoclonal antibody injection) increased significantly against the same period last year. F-627 (Efbemalenograstim alpha, long-acting granulocyte colony-stimulating factor) is currently under marketing application stage. It provides a safety advantage over mainstream second generation products currently on the market, is expected to be approved in China in the first half of 2023.In the area of surgery/analgesia, the Group focused on hospital access and high-potential area development, specifically on developing and increasing coverage of secondary hospitals and community healthcare facilities, driving the rapid growth of Debaian (Flurbiprofen) Cataplasms in the first half of the year.In the area of liver disease, the Group made efforts to strengthen academic promotion so as to expand doctor coverage and enhance expert recognition, as well as actively identified new patients and new market to develop, driving the rapid growth of sales revenue of Tianqing Ganmei Injection during the Period.R&D: Continued to focus on new products in specialist therapeutic areasThe Group has continued to focus R&D efforts on new oncology, surgery/analgesia, hepatitis, respiratory system and cardio-cerebral vascular medicines. As of 30 June 2022, a total of 418 pharmaceutical products had obtained clinical trial approval, or were under clinical trial or applying for production approval. Of them, 29 were for under hepatitis, 230 for oncology, 31 for respiratory system medicines, 9 for endocrine, 16 for cardio-cerebral medicines, 3 for surgery, 4 for analgesia and 96 for other medicines.Prospects: Two-pronged approach of independent research and development, focusing more on products with high innovation and market potentialIn the future, the Group will build a healthier, more diversified and sustainable revenue structure by continuing to build on traditional public hospital sales, invest more resources in new marketing channels and new marketing tools, and gradually expanding their share of revenue. In view of the potential impact of the national volume-based procurement policy on generic drugs, the Group has re-evaluated and optimised its product lines under development from the perspective of innovation and market value, focusing more on products highly innovative and with market potential.The Group will continue to invest more resources in innovative R&D facilities, personnel and projects. Innovation has become a key driver of growth for the Group, with the share of revenue from innovative medicines expected to reach 24% by 2022. Looking ahead, the Group plans to attain revenue exceeding the RMB10 billion mark from innovative medicines by 2023, further increasing the share of revenue from them in the Group's total. The Group aims to become a world-class innovative pharmaceutical group by 2030, with a revenue target of HK$100 billion, of which over 60% is expected to be contributed by innovative drugs.Looking ahead, the Group is focusing on four therapeutic areas, namely oncology, surgery/analgesia, liver disease and respiratory system, and will strive to achieve its 2030 target by adopting a two-pronged approach - pursuing independent research and development and innovation-driven business development.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading, innovative R&D-driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potential, comprising a variety of biopharmaceutical and chemical medicines for oncology, surgery/analgesia, hepatitis, and respiratory system.Sino Biopharmaceutical is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng SCHK Mainland China Healthcare Index, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index, etc.. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Achieves Steady 2022 Q1 Financial Results

HONG KONG, May 13, 2022 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods" or the "Company", and together with its subsidiaries, the "Group"; Stock code: 1475) today announced its unaudited first quarter financial information for the three months ended 31 March 2022 ("the Reporting Period"). The Group's revenue increased by 10.1% year-on-year ("YoY") from HK$964.5 million to HK$1,061.8 million. Gross profit grew 7.4% YoY to HK$332.8 million (2021: HK$309.9 million). Gross profit margin was 31.3% (2021: 32.1%), mainly a result of the increased prices of raw materials and other production costs. Profit attributable to owners of the Company was HK$90.3 million (2021: HK$93.2 million). Revenue from Hong Kong operations increased by 6.6% YoY to HK$357.9 million due to a surge in demand of bag-type instant noodles. As for Mainland China operations, having taken steps to expand its geographical sales territories and strengthen its "Cup Noodles" brand in the Reporting Period, revenue increased by 11.9% (in local currency: 8.6%) to HK$703.9 million, mainly contributed by the growth in sales volume of cup-type instant noodles.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "With the COVID-19 epidemic prevailing, people's livelihood and economic recovery have been surrounded with uncertainties. Although the business environment has been challenging, we are committed to ensuring stable supply of quality and safe products to our customers and, to sustain profit growth. We will continue to enhance production efficiency by improving our capabilities and implementing cost-saving measures. In line with the Company's strategic direction, we will also continue to enhance our product portfolio so as to strengthen overall competitiveness and create sustainable value for all stakeholders."For details, please refer to the announcement:https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0513/2022051300230.pdf About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the "ECO Cup" concept and primarily focuses its sales efforts in first-and second-tier cities. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

China Risun’s 2021 Annual Profit Attributable to Owners Ups 58.1% to RMB2.61 billion

HONG KONG, Mar 28, 2022 - (ACN Newswire via SEAPRWire.com) - China Risun Group Limited ("China Risun", or the "Group", stock code: 1907), a leading global integrated coke, coking chemicals and refined chemicals producer and supplier and relevant operation management services provider in China, has announced its annual results for the year ended 31 December 2021 ("the reporting year"). Profit attributable to owners up 58.1% to RMB2.61 billion, achieving a 3-year consecutive growth since its listing in 2019.Revenue for the year ended 31 December 2021 was RMB38.4 billion, representing an increase of 94.2% year-on-year. Gross profit margin was 14.4% and net profit margin was 6.8%. Basic earnings per share of the Group was RMB61 cents, representing an increase of approximately 52.5% as compared to the figure in 2020. To share the fruit of its outstanding results performance, the Board determined to declare an annual final dividend of RMB6.3 cents per share (equivalent to HK7.7 cents per share), representing no less than 30% of the net profit of the Group. On 7 March, the Group officially switched from a small-cap stock in the Hang Seng Index to a mid-cap stock, and has been included in a number of sub-indexes such as the Hang Seng Large-Mid Cap (Investable) Index and the Shanghai-Hong Kong Stock Connect.Continued expansion of core businesses in coke and refined chemicals industryGlobalization strategy is gradually being implementedIn 2021, the price of coke reached a record high in China, and the profitability of the industry continued to improve. As the core profit source of China Risun, the coke business performed very well. With its national market layout, advantage from large-scale operations and advanced coal blending technology, economies of scale continued to emerge. In 2021, the Group's coke business volume reached 11.5 million tons. The total number of production bases increased to eight, and its core business continued to improve.During the reporting year, the Group continued to expand its market share and gradually implemented its business globalization strategy. The Group's joint venture in Hohhot, Inner Mongolia, is expanding its coke production facilities and is expected to complete in different phases and eventually approximately 3 million tons of coke will commence in operation. Starting from 2021, the Group actively explored opportunities in different places of Asia, for example Sulawesi province, Indonesia. This project is the first overseas coking project held by China Risun. The Group has also participated in two coking projects with an annual output of 4.7 million tons and 3.9 million tons, respectively, in the region. Other than Japan, the Group was considering setting up subsidiaries for trading of raw materials of the coke and refined chemicals industry in Singapore and Indonesia, reflecting the progress its business globalization strategy has made.China Risun has also been expanding its business through methods such as operations management. During the reporting year, China Risun completed the acquisition of two companies and have four operations management companies, expanding the development space and brand influence of its operations management segment, and further consolidating its leading position in the coke and refined chemicals industry.Chemical business steadily expandingExpansion of high value-added products extending industrial chain The refined chemicals segment is another major growth path for China Risun. With the recovery of the global economy and financial easing, chemical products have shaken off the impact of pandemic, and the prices of most products have returned to pre-pandemic levels, which has significantly improved the profitability of the refined chemicals segment. Revenue of this segment up 115.2% to RMB12.6 billion.China Risun has continued to enlarge the capacity of its refined chemicals production facilities. In addition to the 300,000-ton/year styrene production line that was put into operation at the end of 2020, its two-phase caprolactam expansion project is also progressing steadily. In August 2021, the capacity expansion project at the Group's Dongming production base, which comprised capacity expansion, quality improvement and consumption reduction, was successfully completed, expanding the caprolactam capacity from 200,000 tons to 300,000 tons a year, and increasing the Group's existing caprolactam production capacity to 450,000 tons/year. In addition, the second phase of the 300,000 tons/year caprolactam project in the Group's Cangzhou production base is under construction and is expected to commence production in mid-2022. By then, the Group's caprolactam production capacity will reach 750,000 tons a year, which is expected to be the leading player in China.Actively deployed new energy business to become a clean and low-carbon energy supplierAs a global leader in coke production, the Group commenced its entry into the hydrogen energy field in 2020, capitalizing on its advantages from the industrial chain of coke-oven-gas-based hydrogen. Entering 2021, the Group has further developed its hydrogen energy business by actively participated into the hydrogen industrialization plan in Hebei Dingzhou, Inner Mongolia Hohhot and Hebei Xingtai, China. Focusing on the rapid development of hydrogen energy industry in Beijing-TianjinHebei area, the Group is committed to develop from production, storage, transportation, hydrogenation to usage together with radiation of intelligent supply of hydrogen to the whole country with advanced technology and more customer-oriented services. In addition, with the popularity of fuel cell vehicles and the wide application of hydrogen energy in the industrial sector, the Group is expected to become a highly competitive hydrogen energy supplier in Northern China with its advantages in low-cost hydrogen production. Looking forward, the Group will make use of different ways of operation management, merger and acquisition together with the setup of joint ventures with well known geographical large enterprises to increase its market share by production/processing of coke and refined chemicals. The Group will also try to seize opportunities from the explosive growth of hydrogen energy against the backdrop of carbon peaking and carbon neutrality. It is expected to greatly promote the green and low-carbon development of the industry and contribute to the implementation of the national "3060" dual-carbon target strategy. The development plan of the Group's hydrogen energy business has undoubtedly become a model for the transformation and upgrading of the traditional coking industry into a clean energy enterprise, and has also made positive contributions to the Group's high-quality development.About China Risun Group LimitedChina Risun Group Limited is the world's largest independent producer and supplier of coke by volume in 2021, according to Frost & Sullivan. China Risun is an integrated coke, coking chemicals, refined chemicals and hydrogen energy products producer and supplier and relevant operation management services provider in China and occupies leading positions in a number of refined chemicals sectors both in China and globally. The vertically-integrated business model together with more than 27 years of experience in the coal chemicals industry production chain has enabled China Risun to further tap the downstream refined chemicals markets and hence diversify its income sources and create greater value. China Risun has been listed on the main board of the Hong Kong Stock Exchange since March 2019 and is now included in various index series, including the Hang Seng Composite Index, Hang Seng Composite Industry Index - Materials, Hang Seng Composite MidCap Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, Hang Seng Stock Connect Hong Kong Composite Index, Hang Seng Large-Mid Cap (Investable) Index, Hang Seng Large-Mid Cap Low Volatility Comprehensive Index, Hang Seng Large-Mid Cap Quality Comprehensive Index, Hang Seng Large-Mid Cap Low Size Comprehensive Index, Hang Seng Large-Mid Cap Dividend Yield Comprehensive Index, Hang Seng Large-Mid Cap Momentum Comprehensive Index, Hang Seng Large-Mid Cap Value Comprehensive Index, Hang Seng Large-Mid Cap Equal Weighted Factor Mix (QVLM) Index and Hang Seng Large-Mid Cap Risk Parity Factor Mix (QVLM) Index. China Risun is also included in FTSE GEIS: FTSE Global Small Cap Index, FTSE Global All-Cap Index (LMS) and FTSE Global Total-Cap Index (LMSu).For more details, please visit http://www.risun.com/En/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare Included in the Hang Seng Composite Index & Hang Seng Stock Connect Hong Kong Index

HONG KONG, Feb 18, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group has been selected and will be included as a constituent stock of the following index series by Hang Seng Indexes Company Limited, with effect from 7 March 2022: (1) Hang Seng Composite SmallCap Index (2) Hang Seng Small Cap (Investable) Index(3) Hang Seng Healthcare Index (4) Hang Seng Stock Connect Hong Kong Index(5) Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index(6) Hang Seng Stock Connect Hong Kong SmallCap Index(7) Hang Seng SCHK HK Companies Index(8) Hang Seng SCHK ex-AH Companies IndexThe Hang Seng Composite Index ("HSCI") serving as a comprehensive Hong Kong market. HSCI covers the top 95th percentile of the total market capitalisation of companies listed on the Main Board of the Stock Exchange of Hong Kong ("SEHK"). Adopting the freefloat-adjusted market capitalisation methodology, HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks. The HSCI inclusion also implies that the Company are eligible stocks for Stock Connect, which is an important scheme for mutual stock market access between the Mainland and Hong Kong. As EC Healthcare becomes eligible stocks for Stock Connect, the mainland investors can directly trade the Company's stock. are able to deal in the Company's shares directly. This demonstrates the market's recognition of the Company's long-term value and growth potential.Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The inclusion of EC Healthcare in the Hang Seng Composite Index demonstrates the capital market's recognition of the Group's growth potential. As a constituent of the Index and a stock eligible for the Hong Kong Stock Connect, EC Healthcare will be able to further expand its shareholder base and trading liquidity, resulting in realization of the value of investment in the Company and enhancement of the Company's reputation in the capital market. Looking ahead, the Group will continue to refine its business capabilities and further build up the enclosed ecosystem through organic growth as well as mergers and acquisition. This will enable us to provide health management services to more people, create greater value for our clients, thereby creating greater returns for shareholders and leading the industry in upgrading and development."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the MSCI Small Cap Index and the Hang Seng Composite Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine IpTel: (852) 2136 6952 / 2169 0467 / 3920 7649Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Announces Price Revision in Mainland China, Effective 1 March 2022

HONG KONG, Jan 5, 2022 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods", and together with its subsidiaries, the "Group"; Stock code: 1475) will adjust the ex-factory price of its key instant noodle products in Mainland China, effective 1 March 2022. The most recent price adjustments by Nissin Foods on its instant noodles in Mainland China was over a decade ago in 2011. As a leading food manufacturer, the Group has been devoted to enhancing the taste and quality of its products while also ensuring a stable supply of quality instant noodles at reasonable prices for the past 11 years. In face of the increasing cost pressures from the unstable supply and soaring price of raw materials, particularly in the past year, the Group has been working to offset the rising costs by improving its production efficiency and reducing expenses. It has come to the point where the Group found it necessary to adjust its product prices in order to alleviate the cost pressure in a more effective manner. Effective 1 March 2022, Nissin Foods will increase the ex-factory price of its key instant noodle products in Mainland China by a mid-single-digit percentage point on average. The price adjustment will be applied to Cup Noodles, Demae Iccho (bag, cup and bowl types), Nissin Pasta, Raoh and so on. Nissin Foods appreciates the understanding of all business partners and consumers. The Group remains committed to providing safe, tasty and quality products to delight consumers. In addition, Nissin Foods will continue to make investments in order to improve its operational efficiency and enhance its product portfolio, ensuring sustainable growth and creating higher value for shareholders.About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the "ECO Cup" concept and primarily focuses its sales efforts in first-and second-tier cities. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. For media enquiries:Nissin Foods Company LimitedPublic Relations DepartmentBlanche Wong / Riko Lee Email: pr@nissinfoods.com.hkFor investor enquiries:Nissin Foods Company LimitedInvestor Relations DepartmentShingo Yamazaki Email: ir@nissinfoods.com.hkStrategic Financial Relations LimitedVicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hkSharon Lau Tel: (852) 2864 4852 Email: sharon.lau@sprg.com.hkAggie Fang Tel: (852) 2114 4987 Email: aggie.fang@sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Announces 2021 Q3 Financial Results

HONG KONG, Nov 5, 2021 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods", and together with its subsidiaries, the "Group"; Stock code: 1475) has today announced its financial results for the nine months ended 30 September 2021 ("the Reporting Period"). Revenue of the Group increased by 6.4% to HK$2,858.6 million, from HK$2,685.6 million for the corresponding period in 2020. Gross profit increased by 0.4% year-on-year ("YoY") to HK$899.4 million (2020: HK$895.9 million). Gross profit margin stood at 31.5% (2020: 33.4%), which was mainly impacted by the surge in the price of key raw materials and the decrease in revenue from the Hong Kong operations. Profit attributable to owners of the Company was HK$231.4 million (2020: HK$264.0 million). Revenue generated from the PRC operations increased by 12.9% YoY to HK$1,822.1 million from HK$1,614.3 million, attributable to the rise in sales of cup-type instant noodles. With respect to the Hong Kong operations, revenue decreased by 3.2% YoY to HK$1,036.5 million because of the absence of a demand upsurge as experienced last year due to the pandemic, especially in bag-type instant noodles and frozen food. Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "The Group maintains healthy financial metrics with stable contribution from PRC and Hong Kong operations during the Reporting Period. We consider the pursuit of quality a strategic move towards the Group's sustainable growth and success. As part of our product optimisation initiatives, a major product revamp has been made to Cup Noodles this year in celebration of its 50th anniversary. We have successfully realised robust sales in the PRC by pushing forward product optimisation initiatives and taking steps to promote our Cup Noodles brand. At Nissin Foods, we are constantly enhancing our product portfolio and improving our production efficiency. We believe that such efforts will allow us to further understand and satisfy the changing needs of consumers and that of the other stakeholders of the Group."For details, please refer to the announcement:https://www1.hkexnews.hk/listedco/listconews/sehk/2021/1105/2021110500297.pdfAbout Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and the PRC with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the PRC market, the Group has introduced technology innovation through the "ECO Cup" concept into the market and primarily focuses its sales efforts in first-and second-tier cities in the PRC. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Shareholders and senior management show confidence in China Risun by increasing stakes recently

HONG KONG, Nov 2, 2021 - (ACN Newswire via SEAPRWire.com) - Key shareholders and senior management of China Risun Group Limited ("China Risun", or the "Group", stock code: 1907), a leading integrated global coke, coking chemicals and refined chemicals producer and supplier and relevant operation management service provider, have recently time and again increased shareholdings in the Group, indicating their confidence in the Group's development prospects.China Risun's controlling shareholder Texson Limited and Yang Xuegang, Chairman of the Board and CEO of the Group, bought a total of 2.18 million shares of China Risun in the market on average at HK$4.7028 per share and HK$4.54 per share on 27 and 28 October. Subsequently, Texson Limited and Mr. Yang now hold 3.122 billion China Risun shares, and their shareholding together has increased to 70.32%.In addition, according to CCASS public data, the executive directors and senior management of Risun Group have continued to increase their holdings of the company's shares since June 2021.The fundamentals of China Risun remain strong. Currently, the coke inventory of steel mills is at an absolute low level, meaning there is the need for replenishment. In addition, as the winter replenishment gradually starts, the demand for coke is expected to stay stable. Thus, with the current supply and demand situation considered, the spot price of coke is expected to remain strong in the short to medium term. As the business volume and price of coke are expected to be stable, plus the Group has continued to increase production capacity by expanding operation management services and through mergers and acquisitions, its results are set to grow in the medium to long-term.Hydrogen energy business is another growth driver of the Group. In recent years, the Group has made deployment and pursued hydrogen production, storage, transportation and refuelling projects. The first phase of the Dingzhou Hydrogen Energy Base has been completed, with supply covering the Beijing-Tianjin-Hebei region. Furthermore, the Group has also actively participated in hydrogen industrialization projects in Hohhot, Inner Mongolia and Xingtai, Hebei (a hydrogen demonstration city in China). At present, the Group's hydrogen energy business plan in advancing in steady pace with projects gradually implemented and strategic partnerships forged with a good number of companies. As the Group has leading edge when it comes to hydrogen production cost (RMB 0.7-1 m3 only) and craftsmanship, it needs to only fine tune its existing hydrogen production process to produce hydrogen for fuel cells and high purity hydrogen, which have a vast market and very promising prospects.About China Risun Group LimitedChina Risun Group Limited is the world's largest independent producer and supplier of coke by volume in 2020, according to Frost & Sullivan. China Risun is an integrated coke, coking chemicals, refined chemicals and hydrogen energy products producer and supplier and relevant operation management services provider in China and occupies leading positions in a number of refined chemicals sectors both in China and globally. The vertically-integrated business model together with more than 26 years of experience in the coal chemicals industry production chain has enabled China Risun to further tap the downstream refined chemicals markets and hence diversify its income sources and create greater value. China Risun has been listed on the main board of the Hong Kong Stock Exchange since March 2019 and is now included in various index series, including the Hang Seng Composite Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, and Hang Seng SCHK ex-AH Companies Index. For more details, please visit http://www.risun.com/En/ Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Announces 2021 Interim Results

HONG KONG, Aug 30, 2021 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited (the "Company" or "Nissin Foods", and together with its subsidiaries, the "Group"; Stock code: 1475) has today announced its interim results for the six months ended 30 June 2021 ("the reporting period"). The PRC operations continued to perform well during the reporting period, while the Hong Kong operations were hard-hit by the high-base effect benefiting from the "stay-at-home" economy last year. Accordingly, the Group recorded a revenue of HK$1,853.8 million, representing a 6.8% growth year-on-year (2020: HK$1,735.4 million). It is primarily attributable to continuous revenue growth in the PRC operations, offset by the decrease in consumption in the Hong Kong operations. Gross profit was HK$592.3 million (2020: HK$588.0 million) with gross profit margin of 31.9% (2020: 33.9%), mainly attributed to the surge in raw materials prices, the decline in revenue from the Hong Kong operations and the lower contribution from the joint venture distribution business in Shanghai in the first year of its operations. The Group's EBITDA was HK$281.3 million (2020: HK$310.7 million), representing an EBITDA margin of 15.2% (2020: 17.9%). Profit attributable to owners of the Company was HK$170.9 million (2020: HK$178.4 million) with a net profit margin of 9.2% (2020: 10.3%). Profitability was affected during the reporting period as a result of the surge in raw material costs, and the increase in operating and non-operating expenses stemming from the continuous investment in various brands. The rise in costs was, however, compensated by the lower applicable tax rate during the period. Basic earnings per share were 15.94 HK cents (2020: 16.61 HK cents).Hong Kong OperationsRevenue from Hong Kong operations was HK$682.2 million (2020: HK$708.6 million), owing to the absence of sudden surge in demand as in last year's, especially in the bag-type instant noodles and frozen foods. Segment results was HK$52.6 million (2020: HK$97.9 million), mainly attributable to the decline in revenue, the escalating raw material prices since the second half of last year and the brand investment expenses.The Group keeps up its effort to offer original and authentic Japanese delicacy with the launch of the inspirational and popular specialty of Kyushu Oita - fresh yuzu pepper, in tonkotsu soup base for both "Demae Iccho" and "Demae Iccho Bar Noodle" in the reporting period. Celebrating the 50th anniversary of the "Cup Noodles" brand this year, the Group has introduced a bold revamp to the whole series of sixteen flavours of the "Cup Noodles" to revolutionize the noodles quality. To further complement the instant noodles portfolio, the Group has also launched additional offerings under the "ROAH" and "FUKU" brands, together with the broad spectrum of offerings from the "Doll" brand in instant noodles and frozen foods.For non-noodles business, the Group has continued to broaden its product portfolio in Hong Kong. The distribution business has shown a solid improvement as the people resume their normal activities, while the Group's in-house production of granola continued to be one of the consumers' favourite choices. The Group also made further efforts to the KAGOME products during the reporting period. With the products of the vegetable business already reaching the shelf of the supermarkets, the Group foresees it would continue to be a good complement in the long run.To facilitate Nissin Foods' long term development, the Group acquired 100% interest in Ming Fong Packaging & Chemicals Limited ("Ming Fong") at a cash consideration of HK$48.9 million on 14 April 2021.Ming Fong holds a portfolio of plants and machineries and a right-of-use of the land and leasehold property. PRC OperationsRevenue from the PRC operations increased by 14.1% (in local currency: 4.8%) to HK$1,171.6 million (2020: HK$1,026.8 million), thanks to the growth in sales volume from the cup-type instant noodles as customers continued to prefer better quality products. The joint venture distribution business also contributed to the revenue inorganically in the first quarter of 2021. Segment profit increased slightly by 1.8% to HK$145.4 million (2020: HK$142.8 million), mainly attributable to the better control in cost of sales and a prudent investment in branding.Echoing the revamp of "Cup Noodles" in Hong Kong, the Group has had a major product reform in the PRC to celebrate the brand's anniversary. During the reporting period, the Group launched various online and offline marketing and advertising campaigns to foster a stronger sense of brand loyalty and to reinforce a feeling of fashionable and premium brand. The Group also collaborated with different brands to launch crossover packaging for "Cup Noodles" and "ROAH" respectively.With the joint venture distribution business in Shanghai commencing operation in April 2020, the Group has distributed food and beverage under famous third-party Japanese brands and handled the distribution of granola and "KAGOME" products in the PRC. The distribution business has performed up to the Group's expectation during the reporting period.ProspectsLook forward, the soaring raw material prices that have been disrupting the manufacturing process and raising the production costs will remain one of the major concerns in the short run. Nonetheless, the Group is cautiously optimistic about its business outlook and will adopt efficient cost-saving measures to maintain competitiveness during challenging times. In Hong Kong, the launch of the Consumption Voucher Scheme is expected to stimulate consumption in the near term, especially on the small-value items such as the groceries, whereas the gradual increase in the vaccination rates will allow the economy to regain momentum in the medium term.In May 2021, the Group announced an investment plan of approximately HK$194 million to consolidate production facilities and install new smart production lines in Hong Kong. The production facilities will help create a flexible manufacturing system, while the new smart production lines will see higher productivity and management efficiency, as well as better quality control. The construction is expected to complete by 2023.With the consumption continues to improve with higher per capita spending, the Group is confident on its time-proven track record and would continue to expand its business territory in the PRC with sustainable return. Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "At Nissin Foods, we considered it our corporate social responsibility to ensure the stable supply of food, and the pursuit of quality a strategic move towards the Group's success. The Group has thus relentlessly kept serving consumers with consistent product optimisation, lately with Cup Noodles' major product upgrade for instance. While consumption demand has been fluctuating as the global economy continues to reset, the Group has continued to provide better quality products and superior customer experience, a commitment which has helped it sail through good times and bad times. As a responsible corporate citizen, we are dedicated to protecting everyone's wellbeing with stable food supply, and we will continue to stay alert, innovative and persistent in enhancing overall competitiveness, so as to create sustainable long-term value for all stakeholders."For complete information, please refer to the interim results announcement available on the Hong Kong Stock Exchange website at: https://tinyurl.com/4mkarkns About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and the PRC with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the PRC market, the Group has introduced technology innovation through the "ECO Cup" concept into the market and primarily focuses its sales efforts in first-and second-tier cities in the PRC. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic

HONG KONG, Jul 22, 2021 - (ACN Newswire via SEAPRWire.com) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.Henan province has been afflicted by the torrential rain storm and the severe flooding has drawn widespread concern. When a place is in trouble, help from all sides come to the rescue. With this thought in mind, Sino Biopharmaceutical, in fulfilling its social responsibility and living up to its role as a pharmaceutical company dedicated to healthcare, has donated both cash and emergency relief supplies each valued at RMB5 million via the Liaison Office of the Central People's Government in the Hong Kong S.A.R. These funds and supplies are to be used in supporting Henan province's efforts to provide emergency medical and rescue and relief services and prevent the emergence of an outbreak of disease or an epidemic in the wake of the devastation so as to protect the lives, safety and health of the public in Henan. Ms. Cheng Cheung Ling, Vice Chairwoman and Executive Director of Sino Biopharmaceutical, said, "Capitalising on its professional strengths in the biopharmaceutical industry, the Group will closely monitor health issues and epidemic prevention preparations subsequent to this natural disaster, and donate supplies and medicines. Sino Biopharmaceutical regards safeguarding public health as its mission and responsibility. Let's stay together through thick and thin. Keep fighting and don't give up, Henan!"About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for tumors, liver diseases, cardio-cerebral diseases, orthopedic diseases, respiratory system diseases and parenteral nutrition.Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng SCHK Mainland China Healthcare Index, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index, etc.. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.For more information:Strategic Financial Relations LimitedVicky Lee +852 2864 4834 vicky.lee@sprg.com.hkFanny Yuen +852 2864 4853 fanny.yuen@sprg.com.hkMandy Wong +852 2114 4900 mandy.wong@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

China Risun Establish a Joint Venture to Invest In and Construct a Coking Project with an Annual Volume of 4.7 Million Tonnes in Indonesia

HONG KONG, Jul 2, 2021 - (ACN Newswire via SEAPRWire.com) - China Risun Group Limited ("China Risun", or the "Group", stock code: 1907), a leading global integrated coke, coking chemicals and refined chemicals producer and supplier and relevant operation management service provider in China, announced the establishment of a joint venture to invest in and construct a coking project with an annual volume of 4.7 million tonnes in Indonesia. The Group is expanding its business to overseas for the first time.Risun Investments, a wholly-owned subsidiary of China Risun, entered into the Joint VentureAgreement with Tianjin Xintiangang and Stephanie Development, pursuant to which the three parties have agreed to jointly establish, by way of capital injection, De Tian Coking, which will invest in the construction of a coking project (with a capacity of 4.7 million tonnes/year) in Morowali Industrial Park in Sulawesi, Indonesia. The project will have a total investment of approximately US$830 million. Risun Investments will subscribe for US$59.52 million, representing 24% of the registered capital of the Joint Venture. In addition, Risun Investments may also provide shareholder loan in an amount up to approximately US$285 million to De Tian Coking if De Tian Coking is not able to obtain external financing for the project.The Joint Venture plans to invest in and construct a coking project with an annual volume of 4.7 million tonnes in Morowali Industrial Park in Sulawesi, Indonesia, which is one of the exemplary cooperation projects under the Belt and Road Initiative. Dozens of large-scale metal smelting enterprises have or will have business establishments in the park and it is expected that the demand for coke will be enormous in the future. As most of China Risun's production bases are located in the PRC, the transaction will allow the Group to expand its businesses to overseas for the first time. With this transcation, the Group can further reinforce its leadership position as an independent producer and supplier of coke. In addition, by partnering with Tianjin Xintiangan, a renowned steel producers and Stephanie Development, an integrated developer of natural resources, the three parties will able to achieve mutual benefits by jointly establish a new production base in Indonesia.Indonesia is the largest country in Southeast Asia in terms of area, population and gross domestic product. The location of the Joint Venture, namely Bahodopi, Morowali Regency, Central Sulawesi Province, has expedient air, sea and land transportation routes for the supply of coal from Indonesia domestically or from abroad (such as from Australia through sea routes). The majority of the coke products will be sold to Tianjin Xintiangang in the PRC. Therefore, there will be stable supply of coal and sales channel for coke.About China Risun Group LimitedChina Risun Group Limited is the world's largest independent producer and supplier of coke by volume in 2020, according to Frost & Sullivan. China Risun is an integrated coke, coking chemicals and refined chemicals producer and supplier and relevant operation management service provider in China and holds leading positions in a number of refined chemicals sectors both in China and globally. The vertically-integrated business model together with more than 26 years of experience in the coal chemicals industry production chain has enabled China Risun to further tap the downstream refined chemicals markets and hence diversify its income sources and create greater value. China Risun has been listed on the main board of the Hong Kong Stock Exchange since March 2019 and is now included in various index series, including Hang Seng Composite Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, and Hang Seng SCHK ex-AH Companies Index. For more details, please visit http://www.risun.com/En/ Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Champion REIT Secures First Sustainability-Linked Loan

HONG KONG, Jun 8, 2021 - (ACN Newswire via SEAPRWire.com) - Champion Real Estate Investment Trust ("Champion REIT" or "Trust") (Stock Code: 2778), owner of Three Garden Road and Langham Place, has signed its first five-year HK$3.0 billion unsecured sustainability-linked term and revolving credit facilities. The loan proceeds will be used for refinancing and general corporate funding purposes. The loan is backed by:-- DBS Bank Ltd. (as Sustainability Advisor)-- Bank of China (Hong Kong) Limited-- Industrial and Commercial Bank of China (Asia) Limited-- Hang Seng Bank Limited-- The Bank of East Asia, Limited-- Oversea-Chinese Banking Corporation Limited-- Citigroup Global Markets Asia Limited-- United Overseas Bank LimitedBased on the facilities agreement, Champion REIT will receive a discount on the loan's interest rate once the Trust has achieved the pre-determined sustainability-linked performance targets. The sustainability-linked performance targets are based on the aspects of Environmental, Social and Governance ("ESG"): -- Champion REIT achieves reduction of carbon intensity;-- Champion REIT attains WELL Building Standard; and -- Champion REIT retains its listing on the Hang Seng Corporate Sustainability Benchmark index.The targets are aligned with the Trust's 2030 ESG plan, established in 2019, which set the reduction of carbon intensity by 42% as one of the key performance indicators. With the financial incentive, this partnership will reinforce the Trust's commitment to embracing sustainability in every facet of its operations.Over the years, Champion REIT's commitment to sustainability excellence has gained local and international recognition. This includes the WELL Core Certification at Platinum level under the WELL Building Standard by the International WELL Building InstituteTM being awarded to Three Garden Road, making it the first existing building in Hong Kong to score at the highest level of WELL certification. Moreover, the Trust was chosen as a constituent of the Hang Seng Corporate Sustainability Benchmark Index for the fifth consecutive year and was included in the Hang Seng ESG 50 Index in 2020. Ms. Ada Wong, Chief Executive Officer of Champion REIT, said, "Today's announcement marks an important milestone in our sustainability journey and reinforces our commitment to driving ESG's performance over the past several years. This partnership demonstrates well how we have achieved financial value and business benefits by embracing sustainability. In the future, we will continue to explore other possibilities in sustainable financing to drive the Trust strategy forward and bring positive change to society. We are glad to have our relationship banks to support us along this journey and we look forward to building our partnerships together." About Champion REIT (Stock Code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income producing office and retail properties. The Trust focuses on Grade-A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These included two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as joint venture stake in 66 Shoe Lane in Central London. Since 2015, the Trust has been included in the Constituent of Hang Seng Corporate Sustainability Benchmark Index of Hang Seng Indexes.Website: www.championreit.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion

HONG KONG, May 24, 2021 - (ACN Newswire via SEAPRWire.com) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021.Development Highlights-- Chia Tai - Tianqing Pharmaceutical Group Co. Ltd. ("CT Tianqing"), a member company of the Group, and Beijing-based Genetron Holdings Limited (NASDAQ: GTH) signed a strategic cooperation agreement on early screening of liver cancer. The two parties will work together in the next three years in selected areas in the country to serve those at high risk of developing liver cancer, including Hepatitis B carriers and other liver disease patients, thereby establishing industry benchmarks for early liver cancer screening in China and for the world.-- The Group's 6 products, namely Esomeprazole Magnesium Enteric-coated Capsules, Empagliflozin Tablets, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, Canagliflozin Tablets, Bortezomib for Injection and Ticagrelor Tablets, were included in the fourth batch of centralized procurement drugs. Of them, 4 products including Esomeprazole Magnesium Enteric-coated Capsules, are newly approved products which, being qualified for centralized procurement, are expected to quickly gain market share.-- The Group, through its subsidiary C-Lab International Limited, had acquired 100% equity interest in the Belgian private company SOFTHALE NV. SOFTHALE's soft mist inhalation device (SMI) operating on differentiated technology allows more efficient drug deposition in the lungs. It is the next generation transpulmonary drug delivery technology and has good application prospects in treating a board range of diseases such as chronic obstructive pulmonary disease. The Group also plans to through the acquisition build a key strategic hub for development in Europe.-- Fosaprepitant Dimeglumine for Injection, a drug developed by CT Tianqing for prevention of nausea and vomiting caused by chemotherapy, secured approval from the U.S. Food and Drug Administration (FDA). This is another entry pass to international markets obtained by the product, following that from the European Union. It is also another product developed by CT Tianqing that has been granted approval for launch from three mainstream international markets, namely China, the U.S. and Europe.-- Under the guidance of the Beijing Municipal Science and Technology Commission, the Management Committee of the Beijing Economic-Technological Development Area, the Chinese Academy of Medical Sciences and Sino Biopharm, the first "Future Stars" Innovation Achievement Transformation Project Competition hosted by the Institute of Materia Medica at Chinese Academy of Medical Sciences and Beijing Tide Pharmaceutical Co. Ltd., a member company of the Group, was held in Beijing between 6 and 7 January, 2021. The competition has helped enhance mutual understanding between R&D institutions and enterprises, and also presented enterprises an effective mechanism to transform R&D institutions' projects into products.Sales of new products as a percentage to revenue increased to 47.4%, driving revenue up 16.4%; profit attributable to the owners of the parent climbed by 118.5%During the period, the Group recorded revenue of approximately RMB7.24 billion, an increase of approximately 16.4% over the same period last year. Among them, sales of new products amounted to RMB3.43 billion, accounting for approximately 47.4% of the Group's total revenue for the period, up from approximately 32.9% last year. Profit attributable to the owners of the parent was approximately RMB1.91 billion, representing a year-on-year increase of approximately 118.5%. Earnings per share attributable to the owners of the parent were approximately RMB10.19 cents, an increase of approximately 118.7% over the same period last year.The Group's financial position remains strong and stable, cash and bank balances totaled approximately RMB7.93 billion at the period end.The Board of Directors declares a quarterly dividend of HK2 cents per share (Q1 2020: HK2 cents).Building effective marketing by leveraging emerging online platforms amid the pandemic, which in turn boosted product sales; sales of oncology medicines doubledDuring the period, the Group's marketing and sales team was able to accurately grasped opportunities arising from hospitals resuming service with the pandemic under control and more and more patients going to the hospital for consultation. Abiding strictly with pandemic prevention and control policies, marketing activities fully resumed and an effective marketing and service system was formed by integrating the online academic promotion and patient education and service platforms set up during the pandemic.Sales of oncology medicines amounted to approximately RMB2.64 billion, representing an increase of 31.8%. Its contribution has quickly increased to approximately 36.4% and become the Group's largest product category in terms of revenue. With the well-known innovative drug Anlotinib giving the push, and newly launched products in good number and boasting wide coverage of indications, and by giving support to clinical experts in exploring various combined treatment options, Anlotinib as well as other products continued to see fast growth in sales. These products included Qingkeshu (Abiraterone), a prostate cancer drug on the national drug procurement list, the targeted therapy drugs for myeloma, namely Qianping (Bortezomib for injections), Andxian (Lenalidomide capsules), Anyue (Pomalidomide) and Leweixin (Bendamustine Hydrochloride for Injection), the first generic drug Qingkeyi (Fulvestrant Injection) for treating breast cancer, the first generic drug Weishou (Azacitidine for Injection) for treating leukaemia, and the antiemetic drug Shanqi (Fosaprepitant Dimeglumine for Injection).In the cardiovascular and cerebrovascular segment, 8 products developed by the Group were selected in the past 4 rounds of national procurement. To make the best of those related opportunities, the Group worked hard on ensuring smooth production, logistics and supply of its products. As such, products including Tuotuo, Beilishu and Anxinfen reported satisfactory growth.In the field of orthopedic and analgesia, the Group applied its chronic disease management system, well-established and strengthened during the pandemic period, to enhance services for doctors and patients. Gaisanchun (Calcitriol Capsules), Debaian/Zepolas (Flurbiprofen Cataplasms), Yigu (Zoledronic Acid Injection), Kaifen (Flurbiprofen Axetil Injection), Chia Tai Jiuli (Glucosamine Hydrochloride Tablets), Taiyan (Tofacitinib Citrate Tablets), Fenkexin, Yu An (Parecoxib Sodium for Injection), and Sulibao (Celecoxib Capsules) all achieved remarkable sales performance.In the field of respiratory, the Group's first generic drug for allergic asthma, Tianqingsuchang (Budesonide Suspension for Inhalation), was launched, helping enrich the Group's respiratory product line and providing local patients with a new option for the first time other than imported products. At the prompt decision of the medical and marketing departments to set up a hospital service system pinpointing asthma patients, sales of the product increased markedly. Currently, the Group still has a number of respiratory products under development and the area will be one of its main foci in the future. Digestive products, such as Getai (Diosmin Tablets) and Deyou (Pronase), infusion products Fenghaina (Compound Sodium Acelate Ringer's Injection), and contrast products, such as Qingliming (Iodixanol Injection) and Xianai (Gadoxetate Disodium Injection), performed far better than expected during the period.Strong R&D capabilities has been the key profit driverOver the years, the Group has put immense resources into bolstering its R&D capability to turn it into a key profit driver. It has 50 products on sale launched in or after 2018 and their total revenue grew over 90% during the period. The Group's product lines under development have strong reserves of new products to add to every year.During the period, the Group obtained 7 production approvals: 3 specifications of Anlotinib Capsules' New Indication for Medullary Thyroid Carcinoma, 2 specifications of Esomeprazole Magnesium Enteric-coated Capsules, and 2 specifications of Empagliflozin Tablets; and 12 passes of Consistency Evaluation (or are deemed to have passed): 2 specifications of Esomeprazole Magnesium Enteric-coated Capsules (or are deemed to have passed), 2 specifications (or are deemed to have passed) of Empagliflozin Tablets, 2 specifications for Bortezomib for Injections, Parecoxib Sodium for Injection, Docetaxel Injection, 3 specifications of Decitabine for Injection, Alfacalcidol Soft Capsule. 7 pharmaceutical products obtained clinical trial approvals and 8 filed applications for clinical trial. 2 filed applications for production approval and 4 made application for Consistency Evaluation. The Group obtained 39 new invention patent approvals, and made 212 applications for invention patents. Cumulatively, the Group has obtained 963 invention patent approvals. During the period, the total R&D expenditure was approximately RMB1.06 billion, accounting for approximately 14.7% of the Group's revenue.Prospects: deploy the Internet and big data riding on the "Internet + healthcare" national policyAccording to forecasts, the global economic recovery is likely to continue in the second quarter, with further divergence among economies depending on epidemic control, vaccine supply, economic fundamentals and stimulus policies. China's economic activity will continue to show a higher year-on-year growth rate after a full recovery due to its relatively low performance in the same period last year. Health care reform has entered deeper waters. The dynamic adjustment of the National Reimbursement Drug List and the normalization of centralized drug procurement will pave the way for the restructuring of the pharmaceutical industry. R&D innovation capability, production and operational efficiency will be the key to the survival and competitive success of pharmaceutical companies.The Group has been aware of the trend of encouraging and promoting "Internet + healthcare" by national policy, and has started to deploy and will continue to make good use of the Internet and big data to efficiently and cost-effectively conduct academic activities while provide better services to patients through chronic disease management.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for tumors, liver diseases, cardio-cerebral diseases, orthopedic diseases, respiratory system diseases and parenteral nutrition.Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng SCHK Mainland China Healthcare Index, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index, etc.. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Delivers Stable 2021 Q1 Financial Results

HONG KONG, May 11, 2021 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods" or the "Company", and together with its subsidiaries, the "Group"; Stock code: 1475) today announced its unaudited 2021 first quarter financial information for the three months ended 31 March 2021 ("the Reporting Period"). The Group's revenue amounted to HK$964.5 million, representing a year-on-year ("YoY") increase of 9.0% from HK$884.6 million. Gross profit increased by 9.1% YoY to HK$309.9 million (2020: HK$284.2 million), while gross profit margin was maintained at 32.1%, due mainly to the increase in sales in the PRC which offsetted the increase in price of raw materials and other production costs. Profit attributable to owners of the Company was HK$93.2 million (2020: HK$99.0 million). Revenue from the Group's PRC operations increased by 19.5% YoY (in local currency: increased by 11.4%) to HK$628.8 million (2020: HK$526.2 million), attributable mainly to the organic growth of the instant noodles business and contribution from the Group's distribution business. Revenue from the Hong Kong operations amounted to HK$335.6 million (2020: HK$358.4 million), following a decrease in sales of bag-type instant noodles during the Reporting Period. During the Reporting Period, the Group has launched the CUPNOODLES MUSEUM Hong Kong in March. The new attraction showcases the Group's vibrancy and ambition to bring new experiences to Hong Kong people and to inspire creativity and curiosity among visitors via educational and entertaining food-related interaction. The Group also reviews regularly its asset utilisation and efficiency of its production facilities to maintain its leadership position. In line with this strategy, the Group has today announced an investment plan of approximately HK$194 million to consolidate production facilities and install new smart production lines (the "Investment Plan") in its Hong Kong production plants at the Tai Po Industrial Estate. Equipping with advanced production technologies and incorporating state-of-the-art automation and robotics, construction of the new production lines is expected to complete by 2023. The Investment Plan will enhance the Group's production and management efficiency and raise quality control, while ensuring a flexible manufacturing system with an ability to produce a variety of products and provide additional areas for warehousing. Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "Amid the ongoing uncertainties in the global economy since the outbreak of COVID-19 last year, the Group continued to keep serving you, underpinned by our dedication to ensuring a stable supply of affordable, safe and tasty food products in spite of the challenging environment. As a leading food manufacturer, we are committed to investing in a variety of businesses to keep up with the sustainable growth and the integration of advanced technology into the manufacturing process in line with the Group's business development strategy. We will continue investing in our businesses in order to strengthen our overall competitiveness and create sustainable value for our stakeholders."For details, please refer to the announcement:https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0511/2021051100334.pdf About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and the PRC with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the PRC market, the Group has introduced technology innovation through the "ECO Cup" concept into the market and primarily focuses its sales efforts in first-and second-tier cities in the PRC. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Delivers Resilient 2020 Annual Results

HONG KONG, Mar 18, 2021 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods" or the "Company", and together with its subsidiaries, the "Group"; Stock code: 1475) has today announced its annual results for the year ended 31 December 2020. Revenue of the Group increased by 14.0% year-on-year ("YoY") to HK$3,518.8 million (2019: HK$3,087.8 million), primarily due to the satisfactory performance of both the instant noodles and frozen foods businesses in Hong Kong as a result of the recurring waves of the pandemic, as well as the surge in demand for instant noodles in the PRC especially during the first half year. In addition, the joint venture distribution business commenced operation in April 2020 and has contributed to the revenue as at the year. The Group's EBITDA grew by 25.2% YoY to HK$570.0 million (2019: HK$455.4 million) and EBITDA margin increased to 16.2% (2019: 14.7%). Profit attributable to owners of the Company increased by 20.3% YoY to HK$301.9 million (2019: HK$251.0 million), representing a net profit margin of 8.6% (2019: 8.1%). The Group's profitability has improved substantially as a result of the boost in sales among its operating regions and better control of operating and non-operating expenses. Basic earnings per share increased to 28.11 HK cents (2019: 23.36 HK cents) for the year. The Board has resolved to propose a final dividend of 14.05 HK cents per share (2019: 11.7 HK cents), representing a dividend payout ratio of 50.0% (2019: 50.1%). Hong Kong OperationsRevenue from the Hong Kong operations increased by 9.1% YoY to HK$1,418.4 million (2019: HK$1,299.8 million), due to the surge in sales of instant noodles and frozen food, as customers stocked up on food items with longer shelf life and which are easier to prepare. Segment results increased dramatically by 65.5% YoY to HK$165.5 million (2019: HK$100.0 million), mainly due to an upsurge in sales from the instant noodles and non-noodles businesses and better control of cost of sales and selling expenses during the year. With respect to the instant noodles business, the Group has been optimising its product portfolio by launching a series of new products to promote product price optimisation and product upgrade. This is particularly evident in the Group's signature brand "DEMAE ICCHO" which recorded encouraging growth in sales amid the pandemic. Aside from its original offerings, the Group launched Hokkaido Wheat Flour Sesame Oil Flavour Demae Iccho in July 2020. With "CUP NOODLES", the Group further expanded its Western-style flavour collection as well as its Southeast Asian-style flavour collection. Furthermore, the Group has also launched novel offerings under the "UFO", "RAOH", "FUKU" and "DOLL" brands, as well as non-fried noodles under the Bar Ramen and Bar Udon, in order to expand the taste collection for customers amid this difficult time. On the other hand, the Group has consistently diversified its product portfolio, extending to the non-noodles business to expand its product offerings and increase growth in Hong Kong. The Group's strategic moves proved to be a clear success in 2020 despite the impact of COVID-19. Its "DOLL" brand of products were well received by customers for their convenience, and its "KAGOME" brand also performed well due to its advocacy of healthiness. The Group further introduced a new Strawberry Granola for its granola business to enhance its product collection. In addition, the Group invested approximately HK$7.1 million in establishing a pre-packaged ready-to-eat fresh-cut vegetables production line in Hong Kong, so as to cater for the needs of health-conscious customers. The Group also made a capital injection of approximately HK$6.0 million in ValleyFarm Holdings Limited in August 2020. The funds will be used to invest in an indoor hydroponic farm in Hong Kong. The Group foresees a favourable outcome from the vegetable business in the coming years. PRC OperationsRevenue from the PRC operations increased by 17.5% YoY (in local currency: 18.6%) from HK$1,788.0 million in 2019 to HK$2,100.4 million for the year, due to the surge in demand for instant noodles during the first half year. This marks the third consecutive year that the Group has achieved double-digit revenue growth for a full financial year, thus underscoring the Group's track record of success and commitment to its long-term growth in the PRC. Also contributing to revenue growth is the new joint venture distribution business in Shanghai which commenced operation in the second quarter of 2020. Segment results increased by 17.4% YoY to HK$247.1 million (2019: HK$210.6 million), mainly due to the solid performance of the instant noodles business, as well as the additional contribution from the new joint venture distribution business in Shanghai. The Group has continued its geographical expansion efforts, developing in key regions of the PRC during the year, which is in line with its aim of achieving sustainable growth. By investing in infrastructure and people, the Group has delivered satisfactory performance from its "CUP NOODLES" brand and results was especially encouraging for the made-in-Hong Kong "DEMAE ICCHO" brand in its key operating regions in Eastern and Southern China. Further investments were made in Western and Northern China as the Group further expanded its geographical coverage. Besides, the strategic investment of the new joint venture distribution business in Shanghai enabled the Group to further strengthen its business foundation in Eastern China, as well as creating synergy with the Group's current distribution channels as it further expands its business in the PRC. The Group currently distribute a number of famous Japanese brands of snacks food and beverages in the PRC. ProspectsLooking ahead, the Group will continue to make timely adjustments to its production capacity for instant noodles and frozen foods so as to meet customers' needs. For the PRC operations, the Group will further conduct research and development on production as well as strive for product innovations that deliver value to its customers. The Group will also continue expanding its business coverage in the PRC to achieve sustainable growth in the long run. At the same time, efforts will be made to closely monitor and control operating costs. Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "The year 2020 will be remembered as one of the most challenging periods in recent history due to the outbreak of COVID-19. Nevertheless, our dedication to ensuring the steady supply of food to both Hong Kong and the PRC has resulted in the resilient performance of the Group throughout the year. What's more, Nissin Foods has been selected for inclusion in a number of Hang Seng Indexes, thus highlighting the capital market's recognition of our performance and business outlook. Going forward, we will continue to strengthen our overall competitiveness and look for new initiatives to optimise our product mix and broaden our existing product portfolio, in order to satisfy the growing market demand and create long-term value for our stakeholders."For complete information, please refer to the Company's Annual Results Announcement available onthe Hong Kong Stock Exchange website at:https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0318/2021031800371.pdf About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and the PRC with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the PRC market, the Group has introduced technology innovation through the "ECO Cup" concept into the market and primarily focuses its sales efforts in first-and second-tier cities located in the eastern and southern parts of the PRC. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

CUPNOODLES MUSEUM HONG KONG BY NISSIN FOODS SET FOR LAUNCH

HONG KONG, Mar 5, 2021 - (ACN Newswire via SEAPRWire.com) - Today marks the 111th birthday of Momofuku Ando, the Father of Instant Ramen and Founder of Nissin Foods. To celebrate this jubilant day, Nissin Foods is pleased to announce some great news that will excite all travel fans and Japan enthusiasts in particular. CUPNOODLES MUSUEM, one of Japan's flagship travel destinations, is setting for launch in Hong Kong soon at China Hong Kong City, Tsim Sha Tsui. Picture 1: Nissin Foods announces the setting up of CUPNOODLES MUSEUM Hong Kong to celebrate the 111th birthday of Momofuku Ando, the inventor of instant ramenPicture 2: CUPNOODLES MUSEUM Hong Kong pays tribute to Momofuku Ando, who dedicated his entire life to thinking about food in new and creative ways. Pictures 3-4: "My CUPNOODLES Factory" and "Demae Iccho Factory" are coming back in full force, where visitors can create personalized products and explore the fun facts about the ubiquitous cuisine that is always available in every Hong Kong household. Pictures 3-4: "My CUPNOODLES Factory" and "Demae Iccho Factory" are coming back in full force, where visitors can create personalized products and explore the fun facts about the ubiquitous cuisine that is always available in every Hong Kong household. Picture 5: "My Granola Factory" will be the most exclusive workshop in the world where visitors will dive into the story and manufacturing process of granola. Picture 6: "The Big Cup" introduces the reverse thinking concept. Mass production of Cup Noodles was only made possible when Mr. Momofuku Ando applied reverse thinking into production.CUPNOODLES MUSEUM Hong Kong (the "Museum") aims to offer invigorating experiences and renewed aspirations to arouse the curiosity and creativity within every visitor. Tasking with the responsibility to bring innovation to life throughout the Museum, Ching Chai will join the crew as Chief Creative Director. The Museum is neither a duplicate of the ones in Osaka Ikeda and Yokohama nor just a restatement of the two well-received workshops in Hong Kong. Close to 10,000 square foot, the Museum comprises 3 brand-new attractions themed under "The Innovation Journey of Momofuku Ando" and 3 experiential workshops. Of the 3 experiential workshops, "My Granola Factory" will be the most exclusive workshop in the world where visitors can have an immersive experience and dive into the story and manufacturing process of this new product. The iconic workshops, "My CUPNOODLES Factory" and "Demae Iccho Factory", are also coming back in full force, where visitors can create personalized products and explore the fun facts about the ubiquitous cuisine that is always available in every Hong Kong household. Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "Nissin Foods takes it as our corporate social responsibilities (CSR) to keep serving consumers with our food innovation. As a new milestone, introducing CUPNOODLES MUSUEM HONG KONG showcases our vibrancy and ambition in bringing new experiences to Hong Kong people, and inspiring creativity and curiosity for visitors through educational and entertaining interaction related to food. We hope that it will become a popular travel destination and tourists from all over the world can learn and have fun here."More ticketing and opening details will be announced soon. Bookmark CUPNOODLE MUSUEMS Hong Kong and stay tuned! High resolution link: http://bit.ly/3uSlZN1About Nissin Foods Company Limited Nissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and the PRC with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the PRC market, the Group has introduced technology innovation through the "ECO Cup" concept into the market and primarily focuses its sales efforts in first-and second-tier cities located in the eastern and southern parts of the PRC. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Nissin Foods Invests in Frozen Noodles for PRC Market

HONG KONG, Jan 5, 2021 - (ACN Newswire) - Nissin Foods Company Limited ("Nissin Foods", together with its subsidiaries, the "Group"; Stock code: 1475) announced that the Group has made an initial investment in production and storage facilities for frozen noodles in its Shunde Plant in the PRC. A first for the Group in the PRC on frozen noodles, this initiative will not only further enrich its product portfolio, but also capture the growing demand for frozen food products and premium noodles in the PRC. The facilities will commence operation this month, and the products will hit the shelves in the first quarter of 2021. Nissin Foods' first production of frozen noodles in the PRC will hit the shelf in Beijing and Chengdu in the first quarter of this year. The inaugural products are a collaboration with one of the most popular Japanese ramen shops, "Hakata Ikkosha". Two authentic Japanese flavours, namely Hakata Tonkotsu Ramen (Photo 1) and Spicy Tonkotsu Ramen (Photo 2), featuring a rich and creamy pork bone soup base and Japanese Chashu pork with vegetables will be introduced. Introducing Japanese "ice crown manufacturing method" to its production is another first for the Group in the PRC. This method helps retain the original taste, moisture and chewiness of the noodles by wrapping the noodles with ice cubes, akin to putting on an "ice blanket". After heating in a microwave oven for 3 and a half minutes, the ice cubes melt away and the noodles are steamed and moistened in a specially made pouch. With this, consumers can now conveniently prepare the most authentic Japanese premium noodles and enjoy eating at home. The inaugural products are a collaboration with one of the most popular Japanese ramen shops, "Hakata Ikkosha". Two authentic Japanese flavours, namely Hakata Tonkotsu Ramen and Spicy Tonkotsu Ramen, featuring a rich and creamy pork bone soup base with Japanese Chashu pork with vegetables will be introduced. The frozen noodles will be exclusively available at 7-Eleven in Beijing and Chengdu. Separately, the Group's frozen noodles under the "Nissin Foods" brand will also be sold in mid-to high-end supermarkets in the PRC within the year. Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "Year 2021 will be a continuation as well as a new start for Nissin Foods, as we keep enhancing our core instant noodle offering with new innovations while expanding our business with new initiatives. As consumer demand for frozen food products and premium instant noodles continues to gather momentum in the PRC, Nissin Foods is well equipped to capture the growing market with the introduction of premium frozen noodles for the PRC market. We will continue to invest and work with more Japanese ramen shops to develop new flavours and take new initiatives to delight our customers, which in turn will allow us to achieve sustainable business growth and bring fruitful returns to our shareholders."About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and the PRC with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the PRC market, the Group has introduced technology innovation through the "ECO Cup" concept into the market and primarily focuses its sales efforts in first-and second-tier cities located in the eastern and southern parts of the PRC. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. For media enquiries:Nissin Foods Company LimitedPublic Relations DepartmentBlanche Wong / June LauEmail: pr@nissinfoods.com.hkFor investor enquiries:Nissin Foods Company LimitedInvestor Relations DepartmentShingo Yamazaki / Peter KwokEmail: ir@nissinfoods.com.hkStrategic Financial Relations LimitedVicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hkCarven Tsui Tel: (852) 2864 4859 Email: carvensm.tsui@sprg.com.hkCara Lau Tel: (852) 2864 4890 Email: cara.lau@sprg.com.hk Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

Read More